Poland· PL-100383883
Zinplava
A bezlotoxumab product containing bezlotoxumabum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 2 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Bezlotoxumab is registered in 2 of 19 countries.
Countries holding a registration under ATC J06BB21 (bezlotoxumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 1 of them publish a price we can compare per daily dose
Bezlotoxumab · ATC J06BB21
2 / 19 countries
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Bezlotoxumabum
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- J06BB21
- ATC class
- Bezlotoxumab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin00191778000702
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bezlotoxumab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumZinplava 25 mg/mlMerck Sharp & Dohme
- CzechiaZINPLAVAMerck Sharp & Dohme B.V., Haarlem
- FinlandZINPLAVAMerck Sharp & Dohme B.V.
- IrelandZINPLAVA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme BV
- IcelandZinplavaMerck Sharp & Dohme B.V.*
- SwedenZINPLAVA 25 mg/ml Koncentrat till infusionsvätska, lösningMerck Sharp & Dohme BV
- SpainZINPLAVA 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FranceZINPLAVA 25 mg/mL, solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zinplava
- Liechtenstein · Zinplava
- Norway · Zinplava
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6f3f88f7-2445-4132-b595-34507b342dea GET /v1/drugs/6f3f88f7-2445-4132-b595-34507b342dea?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "25 mg/ml",
"packaging": "00191778000702 ¦ Rp ¦ EU/1/16/1156/001 ¦ 120050\n1 fiol. 40 ml\nRp ¦ EU/1/16/1156/002 ¦ 152300\n1 fiol. 25 ml",
"substance": "Bezlotoxumabum 25 mg/ml",
"common_name": "Bezlotoxumabum",
"pl_product_id": "100383883",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about bezlotoxumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.